FDA Approves Twice-Yearly Injectable to Prevent HIV
The FDA has approved a first ever twice-yearly injectable regimen for HIV prevention in adults and adolescents, offering an effective alternative to daily PrEP.
John Serafini, CEO of Hawkeye 360, breaks down the company’s 87% revenue growth, global demand for space-based intelligence and plans to scale its business.